Rosuvastatin is a selective, potent and competitive inhibitor of HMG-CoA reductase effective in lowering low density lipoprotein (LDL) cholesterol and triglycerides. It produces its lipid modifying effects in two ways; firstly it increases the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL and secondly it inhibits the hepatic synthesis of very low density lipoprotein (VLDL), which reduces the total number of VLDL & LDL particles.